Our identification of HDAC6 as a downstream target gene of Smad7 in response to TGF-β is therefore of clinical importance for patients with prostate cancer, as HDAC6-inhibitors are currently investigated for their effects on cancer cells in clinical trials (Wang et al., 2018). This evidence concerns the gene TGFB1 and prostate carcinoma.